FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -Merck and Co and partner Ridgeback Biotherapeutics said on Tuesday they had withdrawn ...

A new study said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other people. But there is no evidence that molnupiravir, sold under the brand ...

As coronavirus concerns increase with the changing of the seasons, the most commonly used oral antiviral treatments are in the spotlight once again. Lagevrio acts by introducing mutations, destroying ...

Feb 21 (Reuters) - Merck & Co Inc (MRK.N), opens new tab said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with ...

Initially hyped as a game-changing COVID-19 treatment, the shine was off Merck and Ridgeback’s oral antiviral Lagevrio (molnupiravir) even before it was authorized for use in the United States.

The first pill shown to treat COVID-19 has moved one step closer to being available to the public. The pharmaceutical company Merck requested FDA emergency authorization Monday for their COVID-19 ...

In a move that could impact vaccine-makers like Merck & Co. Inc. MRK, GSK plc GSK, the U.S. government has decided to ...

The findings may increase scrutiny about the usefulness of the treatment, molnupiravir, which was one of the first Covid drugs available to doctors worldwide during the pandemic. Molnupiravir works by ...